Analysis and Perspectives

Dec 11, 2023

FDA granted accelerated approval to Lilly’s Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma patients.

Dec 04, 2023

In the last two decades, many advancement yielded new insights, paving way for promising therapeutic approaches for dermatomyositis treatment.

Dec 01, 2023

FDA recently approved Amgen’s Wezlana for various inflammatory conditions, marking the first biosimilar approval referencing the J&J Stelara.

Nov 29, 2023

Cryotherapy, a therapeutic technique utilizing extreme cold temperatures, has witnessed a significant evolution catalyzed by technological advancements, propelling its prominence in the healthcare industry. The integration of cutting-edge technology has revolutionized cryotherapy, enabling precise temperature contr...

Nov 27, 2023

The FDA has granted label extensions for two of the most vital global cancer drugs—Merck’s Keytruda and Pfizer and Astellas’ Xtandi.

Nov 24, 2023

On October 31, FDA approved Cosentyx hidradenitis suppurativa treatment, marking first approval of new biologic in nearly a decade.

Nov 22, 2023

In recent years, the joint reconstruction devices market within the realm of orthopedics has undergone a profound evolution, owing to the technological advancements and innovations that have revolutionized treatment modalities and patient outcomes to a much greater extent. The intersection of innovative technologie...

Nov 20, 2023

Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication.

Nov 15, 2023

Rehabilitation equipment, a cornerstone in the realm of healthcare, has undergone a remarkable evolution over the years, propelled by the rising demand and their potential to improve patient outcomes and restore quality of life. From rudimentary tools and manual therapies to the present-day sophisticated, technolog...

Nov 13, 2023

Servier’s Tibsovo has received FDA approval for patients diagnosed with R/R myelodysplastic syndromes that exhibit an IDH1 mutation.